Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluation of the effectiveness and security profile of vedolizumab in inflammatory bowel disease

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: GARCIA SACRISTAN, Ana Andrea (Virgen de la salud Hospital, PHARMACY, toledo, Spain)
  • Co-author(s): Ana Andrea Garcia Sacristan: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Marta Fdz Arévalo: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Cristina Blazquez: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Helena Quirós: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Manuel Martinez Sesmero: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Javier Manzano: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Ana Domiguez: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
    Paloma Moya: hospital phasmacyst, Virgen de la salud Hospital, toledo, Spain
  • Abstract:

    Backgrounds

    Vedolizumab(VD)is a monoclonal antibody-IgG1 indicated in treatment of inflammatory bowel disease(IBD),including ulcerative colitis(UC)and Chron Desease(CD),who has failed other therapies.Pharmacists and Disgestive specialists have worked together to implement a protocol for the correct use of VD

    Aims

    To evaluate effectiveness and safety

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses